Navigation Links
Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development
Date:12/4/2008

LAUSANNE, Switzerland, December 4 /PRNewswire/ -- AC Immune SA, a leader in Alzheimer's disease drug development, announced today that the World Economic Forum has elected AC Immune as Technology Pioneer 2009 for its accomplishments as an innovation leader and for its breakthrough technologies that can have a deep impact on business and society.

Furthermore, AC Immune released that it has reached significant clinical milestones in the development of innovative therapies against Alzheimer's disease. The regulatory authorities have approved the Phase II clinical trial application of the small molecule ACI-91 for the treatment of mild to moderate Alzheimer's disease.

Thirdly, AC Immune disclosed that Genentech Inc., which develops the anti-Abeta antibody under an exclusive license agreement with AC Immune, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the clinical development program in mild to moderate Alzheimer's disease. Enrollment of the first patient in the Phase I clinical study during the third quarter of 2008 triggered a milestone payment to AC Immune of an undisclosed amount.

About AC Immune SA

AC Immune SA is leader in Alzheimer's disease drug development with their corporate headquarters in Ecublens/Lausanne, Switzerland. AC Immune combines its proprietary immunology (SupraAntigen(TM)) and chemistry (Morphomers(TM)) platform technologies to generate conformation-specific Alzheimer's therapies. AC Immune develops innovative therapeutics with "best in class" potential against Alzheimer's Disease along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody for passive immunization is partnered with Genentech and entered clinical Phase I trial in 2008. Two proprietary products, ACI-24 (vaccine) and ACI-91 (small molecule) are entering clinical trials in 2008/2009 and are backed by a rich portfolio of compounds at preclinical stage. Therapeutic molecules are leveraged for Alzheimer's disease diagnostic and other CNS and non-CNS diseases. Since its foundation in 2003, the company has raised CHF24 million in two financing rounds. At the end of 2006, the company closed a more than US$300 million out-licensing agreement with Genentech.

    For the full press release, please go tohttp://www.acimmune.com

    Contact:
    Prof. Andrea Pfeifer
    Chief Executive Officer
    Phone: +41-21-693-91-23
    E-Mail: andrea.pfeifer@acimmune.com
    Internet:http://www.acimmune.com

    Eva Schier
    Corporate Communications Manager
    Phone: +41-21-693-91-34
    E-Mail: eva.schier@acimmune.com
    Internet:http://www.acimmune.com



'/>"/>
SOURCE AC Immune SA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Novel Technology Breaks Through Cancer Pain
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. China Technology Announces New Chief Financial Officer
11. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... states, announced today the promotion of two long-standing principal investigators (PI) to the ... Medicine, Clinical Research and Development. , Dr. Laurence Chu, a Benchmark Research PI ...
(Date:2/10/2016)... Charlotte, NC (PRWEB) , ... February 10, 2016 ... ... highly anticipated expansion to their comprehensive training and support program, Sonalinkā„¢ remote monitoring. ... Sonablate® HIFU procedures performed on Friday, February 5th, connecting Dr. Samuel Peretsman to ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... announced a new agreement with Singapore-based Global Stem Cells Network (GSCN) and its ... Thailand and Singapore in the latest adipose and bone marrow therapies. , ...
Breaking Biology Technology:
(Date:2/1/2016)... 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces the launch of ... Fatone . Las Vegas , where Joey appeared ... Las Vegas , where Joey appeared at the Wocket ... video ad was filmed at the Consumer Electronics Show (CES2016) in ... to meet and greet fans. --> ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. ... in West Chester, Ohio announced ... winning service staff, based in Austin, Texas ... and ability to provide modifications, installations and technical support ... , CEO of PLUS, commented, "PLUS has provided world ...
(Date:1/25/2016)... -- Glencoe Software, the world-leading supplier of image data management ... the data management solution OMERO Plus for the newly ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of cells, ... such as health and disease, the presence or absence ...
Breaking Biology News(10 mins):